MétaCan
Menu
Back to cohort
Record W4416279814 · doi:10.1007/s40262-025-01579-0

Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity

2025· article· en· W4416279814 on OpenAlexaff
Jaydeep Sinha, Kanecia O. Zimmerman, Stephen J. Balevic, Chi D. Hornik, William J. Muller, Mobeen H. Rathore, Marisa Meyer, Yaron Finkelstein, Amira Al‐Uzri, Arpita Lakhotia, Stuart L. Goldstein, Jia‐Yuh Chen, Ravinder Anand, Daniel González, Daniel K. Benjamin, Phyllis Kennel, Cheryl Alderman, Zoë Sund, Kylie Opel, Rose Beci, Gregory L. Kearns, Matthew M. Laughon, Ian M. Paul, Kelly C. Wade, Leanne L. West, Elizabeth Payne, Lily Chen, Gina Simone, Kathleen L. O’Connor, Jennifer Cermak, Lawrence Taylor, Thomas Green, Danny Benjamin, Perdita Taylor‐Zapata, Julie Autmizguine, Edmund V. Capparelli, Rachel G. Greenberg, Terren Green, Ramany John, Ram Yogev, Laura Fearn, Sasidharan Taravath, Tiffony Blanks, Arielle Lapid, Melissa Harward, Nicole Baisden, Kira Clark, Kimberly Grzesek, Charuta Joshi, Austin Drake, Lauri Filar, Jennifer Sargent, Michael Oldham, Julie Burmester, Stephany Eubanks, Terri Simeon, Yael Shiloh‐Malawsky, Christopher L. Anderson, Mallory Jolly, Shradhdha Joshi, Norbert Odero, Jennifer Taylor, Susan Arnold, Caryn R. Harper, Erica N. Howard, María Soledad Castaño Martínez, Deanna Myer, Angela Walker, Ton J. deGrauw, Christopher A. Sims, Benjamin Traisman, Pam Sroka, Carol Nielsen, Kevin Watt, Christie Milleson, Samantha Wrenn, Kathleen Thoma Saniyyah Mahmoudi, Amna Riaz, Alexandrea Borges, Laura P. James, Dawn Hansberry, Michelle Hart, Howard Lee, D Pierce Ann, Karrie Kernen, Susan Poff, Courtney Konow, Kelli R. McCormack Brown, Jen Comings, Andrew Michael, Jackie Perry, Michelle Wiseheart, Janice Bernhardt, Ashley Mariconti, Jennifer Talbert, Glenn Stryjewski, Karen Kowal, Kimberly Klipner, Maggie Rumantir, G. Bradley, Bradley Gerhardt, Cassie Kirby, Bradley DePaoli, Patricia Arnold, Tara Terrell, Theresa Mottes, Daniela Pohl, Hugh McMilan, Roger Zemek, Thierry Lacaze, Sara Leradi, Angie Tuttle, Barbara Murchison, Kyle Patubo, Andrea Kuchler, J. K. Stubbs, Susan Lattimore, Peter M. Mourani, Neil A. Goldenberg, Kevin A Van, Alleluiah Rutebemberwa, Yamila Sierra, Kathryn Malone, Jendar Deschenes, Matthew Steinbeiss, Kimberly Ralston, Gentle Hastenson, Domninic DiDomenico, M C Dix, Catherine Litalien, Vincent Lague, Mariana Dumitrascu, Diane Desmarasis, Christine Massicotte

Bibliographic record

VenueClinical Pharmacokinetics · 2025
Typearticle
Languageen
FieldMedicine
TopicPharmacology and Obesity Treatment
Canadian institutionsHospital for Sick Children
FundersEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institute of Child Health and Human DevelopmentNational Institutes of Health
KeywordsDosingActive metabolitePharmacokineticsOxcarbazepinePopulationObesityPopulation pharmacokinetics

Abstract

fetched live from OpenAlex

BACKGROUND: Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking. OBJECTIVE: This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension. METHODS: Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Nonlinear mixed effects modeling was performed using NONMEM 7.4 to characterize the population pharmacokinetics of OXZ and MHD simultaneously. Simulations were performed to compare MHD systemic exposure in children ≥ 2 years of age with and without obesity. RESULTS: One hundred study participants with a median (range) age of 9 years (44 days-20.90 years) contributed 425 plasma concentrations of OXZ (n = 212) and MHD (n = 213). Fifty-two percent of the participants had obesity. A one-compartment joint parent-metabolite model with linear input-output and bi-directional transformation between OXZ and MHD best characterized the pharmacokinetics. Body size was the only covariate affecting pharmacokinetics, and a fat-free mass-based metric termed pharmacokinetic weight (PKWT) best characterized that effect allometrically. Simulation results revealed that the current dosing regimen of OXZ can produce comparable exposure of MHD in children ≥ 2 years of age with and without obesity. CONCLUSION: A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.090
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.398
Teacher spread0.360 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueClinical PharmacokineticsSame topicPharmacology and Obesity TreatmentFrench-language works237,207